Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/50934
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLloyd M.-
dc.contributor.authorLoke P.-
dc.contributor.authorAshley S.-
dc.contributor.authorLozinsky A.C.-
dc.contributor.authorOrsini F.-
dc.contributor.authorO'Sullivan M.-
dc.contributor.authorGold M.-
dc.contributor.authorQuinn P.-
dc.contributor.authorMetcalfe J.-
dc.contributor.authorTang M.L.-
dc.date.accessioned2024-01-17T02:12:16Z-
dc.date.available2024-01-17T02:12:16Z-
dc.date.copyright2023-
dc.date.issued2024-01-05en
dc.identifier.citationJournal of Allergy and Clinical Immunology: In Practice. 12(4) (pp 1019-1028.e2), 2024. Date of Publication: April 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/50934-
dc.description.abstractBACKGROUND: The PPOIT-003 multi-center randomized trial found that both Probiotic Peanut Oral ImmunoTherapy (PPOIT) and peanut OIT alone (OIT) were effective compared to placebo at inducing clinical remission following 18 months of treatment, and improving health-related quality of life (HRQL) at 12-months post-treatment. Understanding treatment effect modifiers can optimize outcomes through precision care. OBJECTIVE(S): This post hoc study aims to examine baseline clinical and demographic participant factors that modified treatment effects. METHOD(S): Study sample included 201 children (1-10 years) with challenge-confirmed peanut allergy. Exposure variables were baseline clinical and demographic factors. Outcomes were remission (double blind placebo-controlled food challenge, cumulative 4950mg peanut protein, at 8-weeks post-treatment) and HRQL (change in Food Allergy Quality of Life Questionnaire-Parent Form score). Interactions between baseline factors and treatment effects on remission and HRQL were explored with regression models. RESULT(S): A higher degree of peanut sensitivity (large peanut SPT, high peanut sIgE, low reaction eliciting dose at study entry challenge), and other concurrent allergic conditions (multiple food allergies, asthma or wheeze) were associated with decreased likelihood of attaining remission following both PPOIT and OIT treatment. History of anaphylaxis was associated with reduced likelihood of remission after PPOIT compared to OIT. For the HRQL outcome, there was evidence that sex, history of anaphylaxis and age modified treatment effects. CONCLUSION(S): Baseline participant factors modify PPOIT and OIT effects on remission and HRQL. Considering modifiers of treatment effect during participant selection may optimize treatment success and clinical trial design toward specific outcomes, such as achievement of remission.Copyright © 2023. Published by Elsevier Inc.-
dc.relation.ispartofThe Journal of Allergy and Clinical Immunology. In Practice-
dc.subject.meshanaphylaxis-
dc.subject.meshasthma-
dc.subject.meshfood allergy-
dc.subject.meshoral immunotherapy-
dc.titleInteraction between baseline participant factors and treatment effects following peanut oral immunotherapy.-
dc.typeArticle-
dc.type.studyortrialRandomised controlled trial-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.jaip.2023.12.028-
dc.publisher.placeUnited States-
dc.identifier.pubmedid38154554 [https://www.ncbi.nlm.nih.gov/pubmed/?term=38154554]-
dc.identifier.institution(Lloyd) Allergy Immunology, Murdoch Children's Research Institute; Centre for Medicine Use and Safety, Monash University, Melbourne, Australia-
dc.identifier.institution(Loke) Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Monash Children's Hospital, Melbourne, Australia-
dc.identifier.institution(Ashley) Allergy Immunology, Murdoch Children's Research Institute; Department of Paediatrics, University of Melbourne; Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia-
dc.identifier.institution(Lozinsky) Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Australia-
dc.identifier.institution(Orsini) Clinical Epidemiology and Biostatistics, Murdoch Children's Research Institute, Melbourne, Australia-
dc.identifier.institution(O'Sullivan, Metcalfe) Department of Immunology, Perth Children's Hospital, Nedlands WA; Telethon Kid Institute, University of Western Australia, Perth, Australia-
dc.identifier.institution(Gold) University of Adelaide and Department of Allergy and Clinical Immunology, Women's and Children's Health Network, North Adelaide, Australia-
dc.identifier.institution(Quinn) Department of Allergy and Clinical Immunology, Women's and Children's Health Network, North Adelaide, Australia-
dc.identifier.institution(Tang) Allergy Immunology, Murdoch Children's Research Institute; Department of Paediatrics, University of Melbourne; Department of Allergy and Immunology, Royal Children's Hospital, Flemington Rd, Parkville VIC 3052, Australia-
dc.identifier.affiliationmh(Loke) Allergy Immunology, Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Monash Children's Hospital, Melbourne, Australia-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Articles
Show simple item record

Page view(s)

18
checked on Dec 16, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.